v3.26.3
Segments and geographic information
9 Months Ended
Sep. 30, 2026
Segments and geographic information  
Segments and geographic information

12. Segments and geographic information

The Company operates and manages its business as a single operating segment, which is developing a unique class of chemically synthesized medicines based on its proprietary platform. The Company’s chief operating decision maker (“CODM”) is the Company’s Chief Executive Officer (“CEO”). The CODM reviews consolidated operating results, manages the business on a consolidated basis and utilizes consolidated net loss from the consolidated statements of operations and comprehensive loss as the primary measure of segment profit or loss in making decisions surrounding allocating resources and assessing performance of the Company. The CODM is regularly provided detailed expense information, including expenses by program and expense category, and the CODM makes decisions surrounding capital and personnel allocation using this information on a consolidated basis.

​

​

The following table presents information about the Company’s single operating segment, including significant segment expenses, for the three and nine months ended September 30, 2026 and 2025 (in thousands):

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

Three Months Ended

​

Nine Months Ended

​

​

September 30, 

​

September 30, 

​

  ​ ​ ​

2026

  ​ ​ ​

2025

  ​ ​ ​

2026

  ​ ​ ​

2025

Collaboration revenue

​

$

34,057

​

$

11,734

​

$

35,573

​

$

24,631

Significant segment expenses

​

​

​

​

​

​

​

​

​

​

​

​

Research and development:

​

 

  ​

​

 

  ​

​

 

  ​

​

 

  ​

Zelenectide pevedotin (Nectin-4 BDC)

​

​

10,186

​

​

27,461

​

​

50,815

​

​

104,204

Nuzefatide pevedotin (EphA2 BDC)

​

​

2,065

​

​

2,295

​

​

6,751

​

​

6,641

BT1702 (MT1-MMP BRC)

​

​

791

​

​

—

​

​

1,349

​

​

—

Bicycle tumor-targeted immune cell agonists

​

​

56

​

​

484

​

​

947

​

​

1,596

Discovery, platform and other expense

​

​

9,506

​

​

11,969

​

​

26,371

​

​

33,113

Employee and contractor related expenses

​

​

12,441

​

​

18,375

​

​

42,586

​

​

53,919

Share-based compensation

​

​

1,873

​

​

3,645

​

​

7,446

​

​

12,150

Facility expenses

​

​

1,344

​

​

1,814

​

​

4,606

​

​

5,345

Research and development incentives and government grants

​

​

(4,840)

​

​

(7,617)

​

​

(17,388)

​

​

(28,455)

Total research and development

​

​

33,422

​

​

58,426

​

​

123,483

​

​

188,513

General and administrative:

​

​

​

​

​

​

​

​

​

​

​

​

Personnel-related costs

​

​

4,670

​

​

7,305

​

​

17,942

​

​

21,411

Professional and consulting fees

​

​

3,691

​

​

4,113

​

​

9,820

​

​

15,114

Other general and administrative costs

​

​

2,200

​

​

2,473

​

​

6,710

​

​

6,993

Share-based compensation

​

​

3,545

​

​

5,126

​

​

11,306

​

​

15,661

Effect of foreign exchange rates

​

​

6

​

​

(158)

​

​

(170)

​

​

(704)

Total general and administrative

​

​

14,112

​

​

18,859

​

​

45,608

​

​

58,475

Total significant segment expenses

​

​

47,534

​

​

77,285

​

​

169,091

​

​

246,988

Other segment items(1)

​

 

2,999

​

 

6,451

​

 

11,882

​

 

23,551

Segment net loss

​

$

(10,478)

​

$

(59,100)

​

$

(121,636)

​

$

(198,806)

(1)Other segment items include interest and other income, interest expense, and provision for (benefit from) income taxes.

​

The Company does not regularly provide the CODM with detailed segment asset information other than what is included in the condensed consolidated balance sheets. Please refer to the condensed consolidated financial statements and the accompanying notes to the condensed consolidated financial statements for segment asset information.

​

The Company operates in two geographic regions: the United States and the United Kingdom. Information about the Company’s long-lived assets, including operating and finance lease right-of-use assets, held in different geographic regions is presented in the table below (in thousands):

​

​

​

​

​

​

​

​

​

​

September 30, 

​

December 31,

​

  ​ ​ ​

2026

  ​ ​ ​

2025

United States

​

$

200

​

$

863

United Kingdom

​

 

17,447

​

 

21,044

​

​

$

17,647

​

$

21,907

​

The Company’s collaboration revenue is attributed to the operations of the Company in the United Kingdom.